Brind.

Citigroup and Baird lowered their stock targets for Intuitive Surgical on October 19, 2026.

1 report, 1 independent Updated Mon 00:00

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Citigroup Intuitive Surgical Baird

Keep exploring

The entities involved

Citigroup
American investment bank and financial services corporation
- Citigroup restated a buy rating on SAP shares, and Morgan Stanley reiterated an overweight rating on the company.12:27
- Privia Health Group, Inc. shares are listed on the Nasdaq exchange, and Citigroup reissued a buy rating on the stock.12:26
Intuitive Surgical
American corporation
- LabCorp is involved in FDA-approved drugs. Intuitive Surgical's systems were FDA-cleared. Masimo develops noninvasive patient monitoring technologies.Sat 14:22
- Healthcare companies Nihon Kohden and Intuitive Surgical are competing for investment.Fri 08:03
Baird
financial services provider
- Baird seeks regulatory approval in Egypt.Mon 13:51
- Baird strategist Ross Mayfield recommends pivoting to AI adopters like Visa and suggests healthcare and financials as hedges.Sun 10:46

Related events

Multiple wealth management firms and Barclays initiated new investment actions and coverage on Intuitive Surgical.Oct 8

Coverage

Newest first; wire copies grouped

Mon 00:00fool.com